Pfizer discontinues Phase 3 study of Inotuzumab Ozogamicin in relapsed or refractory aggressive Non-Hodgkin Lymphoma (NHL) due to Futility

May 20, 2013 | By Márcio Barra

Seeking Alpha is reporting that Pfizer discountinued a Phase 3 randomized, open-label, two-arm study  evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL), for failling to meet the Primary Endpoint.

In the study, inotuzumab ozogamicin was administered once a month in combination with rituximab, and compared with an active comparator arm, bendamustine plus rituximab or gemcitabine plus rituximab.

During a scheduled interim analysis, an independent Data Monitoring Committee concluded that treatment with inotuzumab ozogamicin plus rituximab would not meet the primary objective of improving overall survival when compared to the comparator arm.

Pfizer says that it will continueto review the the drug for other potential indications.


Seeking Alpha

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: